CXCR2 and neoplasm: Mice that received CAR T cells ectopically expressing chemokine receptors after retroviral transduction with transgenes responded well to tumour rechallenge, with complete regression and surges of CXCR1+ and CXCR2+ CAR T cells at the tumour localities, indicating a long-lasting tumour control capability of the chemokine receptor expressing T cells [38].